Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
VHT vs XLV: Choosing Between Broad Health Care Diversification and Large-Cap Focus

VHT vs XLV: Choosing Between Broad Health Care Diversification and Large-Cap Focus

Key Takeaways

  • VHT tracks the MSCI US Investable Market Health Care 25/50 Index, holding roughly 420 stocks across large, mid, and small capitalization tiers, while XLV tracks the Health Care Select Sector Index and holds only the roughly 60 to 65 health care names in the S&P 500 Index.
  • Both funds are passively managed and market-cap weighted, and their top holdings overlap heavily around mega-cap names such as LLY, JNJ, and ABBV.
  • XLV is slightly cheaper and more concentrated, with a large-cap tilt, whereas VHT offers deeper diversification and broader exposure to smaller health care and biotechnology companies.
  • Cost differences are minimal, with expense ratios near 0.08% to 0.09%, making both among the lowest-cost ways to access U.S. health care equities.
  • Relative performance is driven largely by the same mega-cap pharmaceuticals and managed-care names, meaning the two funds often move together despite different holding counts.

Why Compare These Two Health Care ETFs?

Investors seeking broad U.S. health care exposure frequently compare the Vanguard Health Care ETF (VHT) and the Health Care Select Sector SPDR Fund (XLV). These two funds do not represent different strategies so much as different scopes of the same theme: both are passive, market-cap-weighted vehicles capturing the health care sector, but they draw from different indexes. Understanding where they diverge—breadth of holdings, size exposure, cost, and concentration—can help investors choose the vehicle that best matches their diversification goals and risk tolerance in the current market environment. I also checked this using Tickeron’s AI Screener to see how the two compare across key metrics.

A Closer Look at VHT

VHT is a passively managed ETF that seeks to track the MSCI US Investable Market Health Care 25/50 Index, a benchmark spanning large, mid, and small U.S. health care companies. With roughly 420 holdings, it offers one of the broadest health care portfolios available in an exchange-traded fund, reaching well beyond the mega caps into mid- and small-cap biotechnology, medical devices, and services names. The fund employs a full-replication indexing approach and carries an expense ratio of approximately 0.09%.

Its largest positions include Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK), and UnitedHealth Group (UNH), with additional meaningful weights in Amgen (AMGN), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT). The portfolio is effectively 100% allocated to health care, with a U.S. concentration above 95%. Because of its total-market reach, VHT provides greater exposure to smaller, higher-growth companies than a large-cap-only sector fund.

Understanding XLV

XLV is a passively managed ETF that seeks to track the Health Care Select Sector Index, which comprises the health care constituents of the S&P 500 Index (a widely followed benchmark of large U.S. companies). With approximately 60 to 65 holdings, the fund is far more concentrated than VHT and is dominated by mega-cap pharmaceutical, managed-care, and medical technology companies. Its expense ratio is approximately 0.08%, among the lowest in the health care category.

Top holdings mirror those of VHT but at higher weights: Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK), and UnitedHealth Group (UNH), followed by Thermo Fisher Scientific (TMO) and Amgen (AMGN). Industry exposure skews toward pharmaceuticals, health care equipment and supplies, providers and services, life sciences tools, and biotechnology. As a large-cap-only, non-diversified fund, XLV concentrates risk in its top names but offers the liquidity and familiarity of the S&P 500 ecosystem.

The Broader Health Care Landscape

Both funds operate within a health care sector shaped by several durable catalysts and risks. Drug pricing policy and regulatory scrutiny remain recurring themes, while an aging U.S. population supports long-term demand for pharmaceuticals, devices, and services. Innovation in obesity and metabolic treatments—led by names such as LLY—has been a dominant performance driver in recent market cycles, alongside steady contributions from diversified drugmakers and managed-care providers.

At the same time, the sector is not immune to macroeconomic forces. Health care equities are often viewed as defensive, but interest-rate expectations, earnings cycles among insurers and hospitals, and geopolitical supply-chain considerations can all influence flows. Sector rotation between growth-oriented biotechnology and more defensive pharmaceuticals and payers has shaped relative returns, keeping both ETFs closely tied to the fortunes of a handful of large constituents.

How They’ve Performed and Where They Stand

In recent weeks and months, VHT and XLV have generally tracked each other closely, reflecting their shared mega-cap core. XLV's higher concentration in top holdings such as LLY and JNJ can amplify both upside and downside when those names outperform or lag, while VHT's broader base can smooth returns and provide incremental exposure to smaller, faster-growing biotechnology and device companies.

Both funds carry below-market beta and have historically exhibited lower volatility than the broader equity market, consistent with health care's defensive character. Positioning differences are modest: investors prioritizing deep diversification and small/mid-cap participation may favor VHT, while those seeking concentrated large-cap exposure and marginal cost savings may gravitate toward XLV. From what I see, the overlap in top holdings keeps their day-to-day moves aligned.

Using AI Tools to Compare Sector ETFs

When evaluating sector ETFs like these, I often turn to Tickeron’s AI Screener to quickly filter health care names by volatility, momentum, and holdings overlap. It helps surface how concentration levels affect risk profiles without manually sorting through dozens of data points. The tool’s customizable filters make it straightforward to compare broad versus focused exposure in a single view, which aligns with the kind of analysis I do for portfolio positioning.

My Take on the Choice

Based on observable structural factors, Tickeron’s AI would likely favor XLV as the core large-cap health care allocation, citing its marginally lower expense ratio, deep liquidity, and the strong momentum concentrated in its largest holdings. However, VHT presents a compelling case for investors seeking broader diversification and exposure to smaller, higher-growth health care and biotechnology names. The choice ultimately depends on whether an investor prioritizes concentrated large-cap efficiency or diversified total-market coverage; neither fund offers a clear structural disadvantage. I’m watching this closely as sector flows evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VHT, XLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


VHT sees MACD Histogram crosses below signal line

VHT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 38 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for VHT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 72 cases where VHT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VHT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

VHT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on VHT as a result. In 63 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

VHT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 254 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 208 of 251 cases where VHT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to track the performance of the MSCI U.S. Investable Market Index (IMI)/Health Care 25/50. The fund employs an indexing investment approach designed to track the performance of the index, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the GICS. The Advisor attempts to replicate the target index by seeking to invest all, or substantially all, of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.

Market Cap

The average market capitalization across the Vanguard Health Care ETF (VHT) ETF is 25.9B. The market cap for tickers in the group ranges from 15.62M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is ACH at 15.62M.

High and low price notable news

The average weekly price growth across all stocks in the Vanguard Health Care ETF (VHT) ETF was 113%. For the same ETF, the average monthly price growth was 83%, and the average quarterly price growth was 320%. SLS experienced the highest price growth at 129%, while ACH experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Vanguard Health Care ETF (VHT) ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was -2% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 49
Price Growth Rating: 50
SMR Rating: 80
Profit Risk Rating: 82
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.